Results 61 to 70 of about 15,940 (198)

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

Nature Communications, 2021
Viruses expressing tumour antigens can prime and boost anti-tumour immunity but the efficiency of this approach depends on the capacity of the virus to infect the host.
D. G. Roy, K. Geoffroy, M. Marguerie, S. T. Khan, N. T. Martin, J. Kmiecik, D. Bobbala, A. S. Aitken, C. T. de Souza, K. B. Stephenson, B. D. Lichty, R. C. Auer, D. F. Stojdl, J. C. Bell, M.-C. Bourgeois-Daigneault   +14 more
doaj   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells

Frontiers in Pharmacology, 2017
Oncolytic viral therapy, which makes use of replication-competent lytic viruses, has emerged as a promising modality to treat malignancies. It has shown meaningful outcomes in both solid tumor and hematologic malignancies.
Dhaval S. Sanchala, Lokesh K. Bhatt, Kedar S. Prabhavalkar   +2 more
doaj   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Optimization of CEST MRI Reporter Protein Design Using Cation‐Pi Networks

Chemistry – A European Journal, EarlyView.
A novel engineering approach can produce reporter proteins for cell and viral therapy tracking with unique magnetic resonance imaging (MRI) signatures, detectable with chemical exchange saturation transfer (CEST). We discover how cation‐π interactions between amino acid groups can help us fine‐tune magnetic resonance properties for noninvasive ...
David E. Korenchan, Ethan J. French, Emerenziana Runco, Chetan B. Dhakan, Jinwu Yan, Hiroshi Nakashima, Michael T. McMahon, Assaf A. Gilad, Christian T. Farrar   +8 more
wiley   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

International Journal of Cancer, EarlyView.
What's New? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Microbial metabolites in tumor epigenetic regulation

iMeta, EarlyView.
The gut microbiome modulates tumor epigenetic regulation through bioactive metabolites derived from dietary substrates. Microbiota‐produced SCFAs, secondary BAs, one‐carbon metabolites, and tryptophan‐derived ligands regulate histone acetylation, DNA methylation, and chromatin remodeling via HDAC, DNMT, AhR, and metabolic cofactor‐dependent pathways ...
Wangzheqi Zhang, Haoling Zhang, Yan Liao, Shuya Jiang, Haolong Zhang, Chenwei Huang, Zhijing Song, Rui Zhao, Ping Lu, Xiaohong Kang, Eryan Kong, Yalin Zhu, Wei Wang, Xuesong Liu, Yisheng Chen, Zhiwen Luo, Zhaoyu Li, Di Wang, Na Xing, Yadong Guo, Jingjing Zhang, Xiaojing Wang, Wenyi Wang, Mowaffaq Adam, Bakiah Shaharuddin, Muhamad Yusri Musa, Doblin Sandai, Chenglong Zhu, Aimin Jiang, Peng Luo, Zhijie Zhao, Zui Zou   +31 more
wiley   +1 more source

The impact of innate immune response on the efficacy of oncolytic viruses

Вопросы вирусологии
Oncolytic viruses represent a promising class of immunotherapeutic agents for the treatment of malignant tumors. The proposed mechanism of action of various oncolytic viruses has initially been explained by the ability of such viruses to selectively lyse
Kirill N. Trachuk, Nikolai B. Pestov, Yulia K. Biryukova, Nadezhda M. Kolyasnikova   +3 more
doaj   +1 more source